Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue

Eginhard S. Waldkirch, Stefan Ückert, Kristina Langnäse, Karin Richter, Udo Jonas, Gerald Wolf, Karl Erik Andersson, Christian G. Stief, Petter Hedlund

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives: Phosphodiesterase 5 (PDE5) inhibitors improve smooth muscle relaxation and therefore are considered for pharmacotherapy of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1 (cGKI) has been identified as one of the downstream targets for cGMP. The aim of the present study was to evaluate, by means of immunohistochemistry and Western blot analysis, the expression and localization of cGKI isoforms in relation to smooth muscle α-actin and cGMP in the human prostate. Methods: Cryostat sections of tissue segments excised from the transition zone of human prostates from 11 patients (aged 54-68 yr) were incubated with primary antibodies directed against smooth muscle α-actin, cGMP, cGKI, cGKIα, and cGKIβ. Visualization of double-labelled immunofluorescent staining was achieved by laser microscopy. Western blot analysis was performed to confirm the expression of cGKI isoforms. Results: Immunoreactivities specific for cGKI, cGKIα, and cGKIβ were observed in the smooth musculature of the transition zone. Double-staining revealed the colocalization of smooth muscle α-actin, cGMP, and cGKI isoforms in smooth muscle cells of the fibromuscular stroma. The expression of cGKI isoforms was confirmed by Western blot analysis. Conclusions: Our results confirm the presence of cGKI isoforms α and β in the transition zone of human prostate tissue. In addition, the colocalization of α-actin, cGMP, and cGKI isoforms provides further evidence for a significant role of the nitric oxide/cGMP pathway in the regulation of smooth muscle contractility in human prostate tissue and therefore could provide additional targets for pharmacotherapy of BPH and LUTS.

Original languageEnglish
Pages (from-to)495-502
Number of pages8
JournalEuropean Urology
Volume52
Issue number2
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Cyclic GMP
Prostate
Protein Isoforms
Smooth Muscle
Actins
Lower Urinary Tract Symptoms
Western Blotting
Prostatic Hyperplasia
Staining and Labeling
Phosphodiesterase 5 Inhibitors
Drug Therapy
Muscle Relaxation
Confocal Microscopy
Smooth Muscle Myocytes
Nitric Oxide
Immunohistochemistry
Antibodies

Keywords

  • Benign prostatic hyperplasia
  • Cyclic nucleotides
  • Lower urinary tract symptoms
  • Phosphodiesterase 5
  • Phosphodiesterase 5 inhibitor
  • Protein kinase G

ASJC Scopus subject areas

  • Urology

Cite this

Waldkirch, E. S., Ückert, S., Langnäse, K., Richter, K., Jonas, U., Wolf, G., ... Hedlund, P. (2007). Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue. European Urology, 52(2), 495-502. https://doi.org/10.1016/j.eururo.2007.02.004

Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue. / Waldkirch, Eginhard S.; Ückert, Stefan; Langnäse, Kristina; Richter, Karin; Jonas, Udo; Wolf, Gerald; Andersson, Karl Erik; Stief, Christian G.; Hedlund, Petter.

In: European Urology, Vol. 52, No. 2, 08.2007, p. 495-502.

Research output: Contribution to journalArticle

Waldkirch, ES, Ückert, S, Langnäse, K, Richter, K, Jonas, U, Wolf, G, Andersson, KE, Stief, CG & Hedlund, P 2007, 'Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue', European Urology, vol. 52, no. 2, pp. 495-502. https://doi.org/10.1016/j.eururo.2007.02.004
Waldkirch, Eginhard S. ; Ückert, Stefan ; Langnäse, Kristina ; Richter, Karin ; Jonas, Udo ; Wolf, Gerald ; Andersson, Karl Erik ; Stief, Christian G. ; Hedlund, Petter. / Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue. In: European Urology. 2007 ; Vol. 52, No. 2. pp. 495-502.
@article{2ae9707fdb214c24826d120bb8af684f,
title = "Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue",
abstract = "Objectives: Phosphodiesterase 5 (PDE5) inhibitors improve smooth muscle relaxation and therefore are considered for pharmacotherapy of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1 (cGKI) has been identified as one of the downstream targets for cGMP. The aim of the present study was to evaluate, by means of immunohistochemistry and Western blot analysis, the expression and localization of cGKI isoforms in relation to smooth muscle α-actin and cGMP in the human prostate. Methods: Cryostat sections of tissue segments excised from the transition zone of human prostates from 11 patients (aged 54-68 yr) were incubated with primary antibodies directed against smooth muscle α-actin, cGMP, cGKI, cGKIα, and cGKIβ. Visualization of double-labelled immunofluorescent staining was achieved by laser microscopy. Western blot analysis was performed to confirm the expression of cGKI isoforms. Results: Immunoreactivities specific for cGKI, cGKIα, and cGKIβ were observed in the smooth musculature of the transition zone. Double-staining revealed the colocalization of smooth muscle α-actin, cGMP, and cGKI isoforms in smooth muscle cells of the fibromuscular stroma. The expression of cGKI isoforms was confirmed by Western blot analysis. Conclusions: Our results confirm the presence of cGKI isoforms α and β in the transition zone of human prostate tissue. In addition, the colocalization of α-actin, cGMP, and cGKI isoforms provides further evidence for a significant role of the nitric oxide/cGMP pathway in the regulation of smooth muscle contractility in human prostate tissue and therefore could provide additional targets for pharmacotherapy of BPH and LUTS.",
keywords = "Benign prostatic hyperplasia, Cyclic nucleotides, Lower urinary tract symptoms, Phosphodiesterase 5, Phosphodiesterase 5 inhibitor, Protein kinase G",
author = "Waldkirch, {Eginhard S.} and Stefan {\"U}ckert and Kristina Langn{\"a}se and Karin Richter and Udo Jonas and Gerald Wolf and Andersson, {Karl Erik} and Stief, {Christian G.} and Petter Hedlund",
year = "2007",
month = "8",
doi = "10.1016/j.eururo.2007.02.004",
language = "English",
volume = "52",
pages = "495--502",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue

AU - Waldkirch, Eginhard S.

AU - Ückert, Stefan

AU - Langnäse, Kristina

AU - Richter, Karin

AU - Jonas, Udo

AU - Wolf, Gerald

AU - Andersson, Karl Erik

AU - Stief, Christian G.

AU - Hedlund, Petter

PY - 2007/8

Y1 - 2007/8

N2 - Objectives: Phosphodiesterase 5 (PDE5) inhibitors improve smooth muscle relaxation and therefore are considered for pharmacotherapy of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1 (cGKI) has been identified as one of the downstream targets for cGMP. The aim of the present study was to evaluate, by means of immunohistochemistry and Western blot analysis, the expression and localization of cGKI isoforms in relation to smooth muscle α-actin and cGMP in the human prostate. Methods: Cryostat sections of tissue segments excised from the transition zone of human prostates from 11 patients (aged 54-68 yr) were incubated with primary antibodies directed against smooth muscle α-actin, cGMP, cGKI, cGKIα, and cGKIβ. Visualization of double-labelled immunofluorescent staining was achieved by laser microscopy. Western blot analysis was performed to confirm the expression of cGKI isoforms. Results: Immunoreactivities specific for cGKI, cGKIα, and cGKIβ were observed in the smooth musculature of the transition zone. Double-staining revealed the colocalization of smooth muscle α-actin, cGMP, and cGKI isoforms in smooth muscle cells of the fibromuscular stroma. The expression of cGKI isoforms was confirmed by Western blot analysis. Conclusions: Our results confirm the presence of cGKI isoforms α and β in the transition zone of human prostate tissue. In addition, the colocalization of α-actin, cGMP, and cGKI isoforms provides further evidence for a significant role of the nitric oxide/cGMP pathway in the regulation of smooth muscle contractility in human prostate tissue and therefore could provide additional targets for pharmacotherapy of BPH and LUTS.

AB - Objectives: Phosphodiesterase 5 (PDE5) inhibitors improve smooth muscle relaxation and therefore are considered for pharmacotherapy of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1 (cGKI) has been identified as one of the downstream targets for cGMP. The aim of the present study was to evaluate, by means of immunohistochemistry and Western blot analysis, the expression and localization of cGKI isoforms in relation to smooth muscle α-actin and cGMP in the human prostate. Methods: Cryostat sections of tissue segments excised from the transition zone of human prostates from 11 patients (aged 54-68 yr) were incubated with primary antibodies directed against smooth muscle α-actin, cGMP, cGKI, cGKIα, and cGKIβ. Visualization of double-labelled immunofluorescent staining was achieved by laser microscopy. Western blot analysis was performed to confirm the expression of cGKI isoforms. Results: Immunoreactivities specific for cGKI, cGKIα, and cGKIβ were observed in the smooth musculature of the transition zone. Double-staining revealed the colocalization of smooth muscle α-actin, cGMP, and cGKI isoforms in smooth muscle cells of the fibromuscular stroma. The expression of cGKI isoforms was confirmed by Western blot analysis. Conclusions: Our results confirm the presence of cGKI isoforms α and β in the transition zone of human prostate tissue. In addition, the colocalization of α-actin, cGMP, and cGKI isoforms provides further evidence for a significant role of the nitric oxide/cGMP pathway in the regulation of smooth muscle contractility in human prostate tissue and therefore could provide additional targets for pharmacotherapy of BPH and LUTS.

KW - Benign prostatic hyperplasia

KW - Cyclic nucleotides

KW - Lower urinary tract symptoms

KW - Phosphodiesterase 5

KW - Phosphodiesterase 5 inhibitor

KW - Protein kinase G

UR - http://www.scopus.com/inward/record.url?scp=34250774010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250774010&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2007.02.004

DO - 10.1016/j.eururo.2007.02.004

M3 - Article

C2 - 17329019

AN - SCOPUS:34250774010

VL - 52

SP - 495

EP - 502

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -